Diabetes Mellitus and Advanced Liver Fibrosis Are Risk Factors for Severe Anemia During Telaprevir-based Triple Therapy

Por Crismale, James F., Martel-Laferrière, Valérie, Bichoupan, Kian, Schonfeld, Emily, Pappas, Alexis, Wyatt, Christina, Odin, Joseph A., Liu, Lawrence U., Schiano, Thomas D., Perumalswami, Ponni V., Bansal, Meena, Dieterich, Douglas T., Branch, Andrea D.
Publicado em 2013

Costs of Telaprevir-based Triple Therapy for Hepatitis C: $189,000 per Sustained Virologic Response

Por Bichoupan, Kian, Martel-Laferriere, Valerie, Sachs, David, Ng, Michel, Schonfeld, Emily A., Pappas, Alexis, Crismale, James, Stivala, Alicia, Khaitova, Viktoriya, Gardenier, Donald, Linderman, Michael, Perumalswami, Ponni V., Schiano, Thomas D., Odin, Joseph A., Liu, Lawrence, Moskowitz, Alan J., Dieterich, Douglas T., Branch, Andrea D.
Publicado em 2014

Factors associated with success of telaprevir- and boceprevir-based triple therapy for hepatitis C virus infection

Por Bichoupan, Kian, Tandon, Neeta, Martel-Laferriere, Valerie, Patel, Neal M, Sachs, David, Ng, Michel, Schonfeld, Emily A, Pappas, Alexis, Crismale, James, Stivala, Alicia, Khaitova, Viktoriya, Gardenier, Donald, Linderman, Michael, Olson, William, Perumalswami, Ponni V, Schiano, Thomas D, Odin, Joseph A, Liu, Lawrence U, Dieterich, Douglas T, Branch, Andrea D
Publicado no World J Hepatol (2017)